首页 > 最新文献

Global health & medicine最新文献

英文 中文
Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma. 播散性结节外大 B 细胞淋巴瘤(包括血管内大 B 细胞淋巴瘤)的前瞻性治疗研究。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-08-31 DOI: 10.35772/ghm.2024.01021
Tomoyuki Sakai, Yusuke Ueda, Hiroto Yanagisawa, Kotaro Arita, Haruka Iwao, Kazunori Yamada, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Katsunori Tai, Shinji Kishi, Koji Morinaga, Jun Murakami, Hiroyuki Takamatsu, Yasushi Terasaki, Nobuyuki Yoshio, Yukio Kondo, Hirokazu Okumura, Sadaya Matano, Masaki Yamaguchi, Hiroshi Tsutani, Yasufumi Masaki

This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.

这项研究旨在为包括血管内大B细胞淋巴瘤(DEN-LBCL/IVL)在内的播散性结节外大B细胞淋巴瘤制定标准治疗方法,并验证我们提出的临床诊断标准。2006年至2016年间,北陆血液肿瘤学研究小组的一项临床试验共招募了22名患者。第一周期化疗包括减量的环磷酰胺、多柔比星、长春新碱和泼尼松龙(CHOP),并延迟使用利妥昔单抗。从第二个周期到第六个周期,患者接受常规的利妥昔单抗和CHOP治疗。主要终点是总生存期(OS),次要终点包括完全应答率(CR)和治疗失败时间(TTF)。结果显示,CR率为73%,中位OS为65个月,中位TTF为45个月。这些结果表明,DEN-LBCL/IVL患者可以通过我们的新型化疗免疫疗法方案得到有效治疗。我们的临床诊断标准有助于识别需要早期干预的患者。
{"title":"Prospective therapeutic studies of disseminated extranodal large B-cell lymphoma including intravascular large B-cell lymphoma.","authors":"Tomoyuki Sakai, Yusuke Ueda, Hiroto Yanagisawa, Kotaro Arita, Haruka Iwao, Kazunori Yamada, Shuichi Mizuta, Hiroshi Kawabata, Toshihiro Fukushima, Katsunori Tai, Shinji Kishi, Koji Morinaga, Jun Murakami, Hiroyuki Takamatsu, Yasushi Terasaki, Nobuyuki Yoshio, Yukio Kondo, Hirokazu Okumura, Sadaya Matano, Masaki Yamaguchi, Hiroshi Tsutani, Yasufumi Masaki","doi":"10.35772/ghm.2024.01021","DOIUrl":"10.35772/ghm.2024.01021","url":null,"abstract":"<p><p>This study aimed to establish a standard treatment for disseminated extranodal large B-cell lymphoma, including intravascular large B-cell lymphoma (DEN-LBCL/IVL), and to validate the clinical diagnostic criteria we proposed. Between 2006 and 2016, 22 patients were enrolled in a clinical trial conducted by the Hokuriku Hematology Oncology Study Group. The first cycle of chemotherapy consisted of dose-reduced cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) with delayed administration of rituximab. From the second to the sixth cycle, patients received conventional rituximab and CHOP therapy. The primary endpoint was overall survival (OS), while the secondary endpoints included the complete response (CR) rate and time to treatment failure (TTF). The results showed a CR rate of 73%, a median OS of 65 months, and a median TTF of 45 months. These findings indicate that patients with DEN-LBCL/IVL were effectively treated with our new chemoimmunotherapy regimen. Our clinical diagnostic criteria are useful for identifying patients who require early intervention.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 4","pages":"277-281"},"PeriodicalIF":1.9,"publicationDate":"2024-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11350362/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142106360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Human papilloma virus (HPV)-related information acquisition and seeking behavior among infected women: A single center cross-sectional survey in Shanghai, China. 感染人乳头瘤病毒(HPV)的女性获取相关信息和寻求信息的行为:中国上海单中心横断面调查。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2023.01100
Xiehua Yuan, Linlin Lu, Ruhe Jiang, Yue Yu, Jing Zhou, Ling Wang, Yan Du

Lacking of adequate knowledge is an obstacle to effective prevention of cervical cancer, yet factors that affect the information acquisition and seeking behavior as well as the information communication process are not well studied. We assessed information acquisition and seeking behavior, as well as perceived barriers of doctor-patient communication regarding human papilloma virus (HPV)-related information of infected women. Among 437 participants, 405 (93%) expressed demands for HPV-related information, while only a small proportion (100/437, 22.9%) actively sought information and felt obstacles comprehending. Web-based channels were most frequently utilized and medical personnel were the most trusted information source. Patients' satisfaction was significantly correlated with doctor's patience (r = 0.581, p < 0.001) and emotional caring (r = 0.555, p < 0.001). Compared to patients not actively seeking information, those actively seeking information were more likely to be single (p = 0.005), had higher education (p = 0.009) and monthly individual-level income (p = 0.023), and was more likely to undergo regular cervical cancer screening (p = 0.003), and were already or willing to be vaccinated (p = 0.008). The actively seeking information group also achieved higher scores in HPV knowledge test (p = 0.007). Public health interventions targeting HPV-infected women using specifically designed educational materials may influence information seeking behavior, increase HPV literacy and knowledge, which could potentially increase HPV vaccine uptake and cervical cancer screening rate.

缺乏足够的知识是有效预防宫颈癌的一个障碍,然而影响信息获取和寻求行为以及信息沟通过程的因素却没有得到很好的研究。我们评估了受感染妇女的信息获取和寻求行为,以及对人类乳头瘤病毒(HPV)相关信息的医患沟通障碍的感知。在 437 名参与者中,405 人(93%)表达了对人乳头瘤病毒相关信息的需求,而只有一小部分人(100/437,22.9%)积极寻求信息,并在理解上感到障碍。网络渠道最常用,医务人员是最值得信赖的信息来源。患者的满意度与医生的耐心(r = 0.581,p < 0.001)和情感关怀(r = 0.555,p < 0.001)明显相关。与不主动寻求信息的患者相比,主动寻求信息的患者更有可能是单身(p = 0.005)、受过高等教育(p = 0.009)和有个人月收入(p = 0.023)、更有可能定期接受宫颈癌筛查(p = 0.003)、已经或愿意接种疫苗(p = 0.008)。积极寻求信息组在 HPV 知识测试中的得分也更高(p = 0.007)。使用专门设计的教育材料对受 HPV 感染的妇女进行公共卫生干预,可能会影响其寻求信息的行为,增加对 HPV 的了解和知识,从而有可能提高 HPV 疫苗的接种率和宫颈癌筛查率。
{"title":"Human papilloma virus (HPV)-related information acquisition and seeking behavior among infected women: A single center cross-sectional survey in Shanghai, China.","authors":"Xiehua Yuan, Linlin Lu, Ruhe Jiang, Yue Yu, Jing Zhou, Ling Wang, Yan Du","doi":"10.35772/ghm.2023.01100","DOIUrl":"10.35772/ghm.2023.01100","url":null,"abstract":"<p><p>Lacking of adequate knowledge is an obstacle to effective prevention of cervical cancer, yet factors that affect the information acquisition and seeking behavior as well as the information communication process are not well studied. We assessed information acquisition and seeking behavior, as well as perceived barriers of doctor-patient communication regarding human papilloma virus (HPV)-related information of infected women. Among 437 participants, 405 (93%) expressed demands for HPV-related information, while only a small proportion (100/437, 22.9%) actively sought information and felt obstacles comprehending. Web-based channels were most frequently utilized and medical personnel were the most trusted information source. Patients' satisfaction was significantly correlated with doctor's patience (<i>r</i> = 0.581, <i>p</i> < 0.001) and emotional caring (<i>r</i> = 0.555, <i>p</i> < 0.001). Compared to patients not actively seeking information, those actively seeking information were more likely to be single (<i>p</i> = 0.005), had higher education (<i>p</i> = 0.009) and monthly individual-level income (<i>p</i> = 0.023), and was more likely to undergo regular cervical cancer screening (<i>p</i> = 0.003), and were already or willing to be vaccinated (<i>p</i> = 0.008). The actively seeking information group also achieved higher scores in HPV knowledge test (<i>p</i> = 0.007). Public health interventions targeting HPV-infected women using specifically designed educational materials may influence information seeking behavior, increase HPV literacy and knowledge, which could potentially increase HPV vaccine uptake and cervical cancer screening rate.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"212-217"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197161/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467421","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma. 肝细胞癌晚期系统治疗时代的肝切除术作用。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2024.01002
Norihiro Kokudo, Takashi Kokudo, Peipei Song, Wei Tang

The recent dramatic progress in systemic therapy for hepatocellular carcinoma (HCC) provides the possibility of a combination of surgery and systemic therapy including adjuvant, neoadjuvant, or conversion settings. Since the turn of the century, at least three negative studies have tested adjuvant therapies after curative resection or ablation, including uracil-tegafur, which is an oral chemotherapeutic drug, sorafenib, and peretinoin, which a synthetic retinoid that may induce the apoptosis and differentiation of liver cancer cells. Using more potent immuno-checkpoint inhibitors (ICIs), at least 4 phase III trials of adjuvant immunotherapy are ongoing: nivolumab, durvalumab/ bevacizumab, pembrolizumab, and atezolizumab+bevacizumab. Very recently, the last trial indicated a significantly better recurrence-free survival (RFS) for adjuvant atezolizumab+bevacizumab. Another promising combination of surgery and systemic therapy is neoadjuvant therapy for potentially resectable cases or a conversion strategy for oncologically unresectable cases. There are 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: the LENS-HCC trial using lenvatinib and the RACB study using atezolizumab+bevacizumab. A longer follow-up may be needed, but the overall survival (OS) in resected cases seems much higher than that in unresectable cases. Recently, the Japan Liver Cancer Association (JLCA) and the Japanese Society of HPB Surgery (JSHPBS) created a joint working group on "so-called borderline resectable HCC". They obtained a Japanese consensus on this issue that has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides a common language regarding advanced HCC for investigators and is a useful tool for future clinical trials.

最近,肝细胞癌(HCC)的全身治疗取得了巨大进展,为手术和全身治疗(包括辅助治疗、新辅助治疗或转换治疗)的结合提供了可能。自本世纪初以来,至少有三项阴性研究对治愈性切除或消融术后的辅助疗法进行了测试,包括脲嘧啶-替加氟(一种口服化疗药物)、索拉非尼和培非诺(一种合成维甲酸,可诱导肝癌细胞凋亡和分化)。目前,至少有 4 项辅助免疫疗法的 III 期试验正在使用更强效的免疫检查点抑制剂(ICIs):nivolumab、durvalumab/贝伐珠单抗、pembrolizumab 和 atezolizumab+贝伐珠单抗。最近的一项试验表明,阿特珠单抗+贝伐单抗辅助治疗的无复发生存期(RFS)明显更好。手术和全身治疗的另一个有前途的组合是对可能切除的病例进行新辅助治疗,或对肿瘤学上无法切除的病例采取转换策略。日本正在进行两项针对技术上或肿瘤学上无法切除的HCC的新辅助治疗试验:使用来伐替尼的LENS-HCC试验和使用阿特珠单抗+贝伐单抗的RACB研究。可能需要更长时间的随访,但切除病例的总生存率(OS)似乎远高于无法切除的病例。最近,日本肝癌协会(JLCA)和日本 HPB 外科学会(JSHPBS)成立了一个关于 "所谓的可切除边界型 HCC "的联合工作组。他们就这一问题达成了日本共识,并在 JLCA 和 JSHPBS 的网站上公布。可切除性或边缘可切除性的定义为研究人员提供了有关晚期 HCC 的共同语言,是未来临床试验的有用工具。
{"title":"Role of liver resection in the era of advanced systemic therapy for hepatocellular carcinoma.","authors":"Norihiro Kokudo, Takashi Kokudo, Peipei Song, Wei Tang","doi":"10.35772/ghm.2024.01002","DOIUrl":"10.35772/ghm.2024.01002","url":null,"abstract":"<p><p>The recent dramatic progress in systemic therapy for hepatocellular carcinoma (HCC) provides the possibility of a combination of surgery and systemic therapy including adjuvant, neoadjuvant, or conversion settings. Since the turn of the century, at least three negative studies have tested adjuvant therapies after curative resection or ablation, including uracil-tegafur, which is an oral chemotherapeutic drug, sorafenib, and peretinoin, which a synthetic retinoid that may induce the apoptosis and differentiation of liver cancer cells. Using more potent immuno-checkpoint inhibitors (ICIs), at least 4 phase III trials of adjuvant immunotherapy are ongoing: nivolumab, durvalumab/ bevacizumab, pembrolizumab, and atezolizumab+bevacizumab. Very recently, the last trial indicated a significantly better recurrence-free survival (RFS) for adjuvant atezolizumab+bevacizumab. Another promising combination of surgery and systemic therapy is neoadjuvant therapy for potentially resectable cases or a conversion strategy for oncologically unresectable cases. There are 2 neoadjuvant trials for technically or oncologically unresectable HCCs ongoing in Japan: the LENS-HCC trial using lenvatinib and the RACB study using atezolizumab+bevacizumab. A longer follow-up may be needed, but the overall survival (OS) in resected cases seems much higher than that in unresectable cases. Recently, the Japan Liver Cancer Association (JLCA) and the Japanese Society of HPB Surgery (JSHPBS) created a joint working group on \"so-called borderline resectable HCC\". They obtained a Japanese consensus on this issue that has been published on the websites of JLCA and JSHPBS. The definition of resectability or borderline resectability provides a common language regarding advanced HCC for investigators and is a useful tool for future clinical trials.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"170-173"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197156/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
"Fertility-friendly hospitals": A key measure to promote long-term and balanced population development in China. "生育友好型医院":促进中国人口长期均衡发展的关键举措。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2024.01027
Jingyi Ma, Fei Ma, Heng Zou

In response to the twin challenges of an aging population and declining birth rates, Zhejiang, China pioneered the concept of "fertility-friendly hospitals" in 2022 to support families and individuals in navigating the complexities of childbirth. Although fertility-friendly hospitals have not yet scaled up in number, their potential benefits and the challenges they face are evident. These facilities aim to provide comprehensive services from preconception to postnatal care, necessitating a high level of specialization and resource allocation, with an emphasis on patient education and participatory decision-making. Currently, there is an uneven distribution of resources across regions in China, with the density of maternal and child health care facilities in developed areas exceeding that of less developed regions by more than tenfold. The establishment of fertility-friendly hospitals will help to slow the pace of population aging and mitigate further declines in birth rates, thereby balancing the population composition and promoting long-term equitable social development. However, they also face challenges in balancing resources, improving the quality of services, and improving accessibility across different regions. As the concept is promoted and practiced, fertility-friendly hospitals are expected to become a significant force supporting Chinas population policy.

为应对人口老龄化和出生率下降的双重挑战,中国浙江于 2022 年率先提出了 "生育友好医院 "的概念,以支持家庭和个人应对复杂的生育问题。虽然生育友好型医院的数量尚未扩大,但其潜在效益和面临的挑战显而易见。这些设施旨在提供从孕前到产后护理的全面服务,需要高度的专业化和资源分配,并强调患者教育和参与式决策。目前,中国各地区资源分配不均,发达地区的妇幼保健机构密度是欠发达地区的十倍以上。建立生育友好型医院有助于延缓人口老龄化速度,缓解出生率进一步下降的问题,从而平衡人口构成,促进社会长期公平发展。然而,这些医院也面临着平衡资源、提高服务质量、改善不同地区可及性等方面的挑战。随着这一理念的推广和实践,生育友好型医院有望成为支持中国人口政策的重要力量。
{"title":"\"Fertility-friendly hospitals\": A key measure to promote long-term and balanced population development in China.","authors":"Jingyi Ma, Fei Ma, Heng Zou","doi":"10.35772/ghm.2024.01027","DOIUrl":"10.35772/ghm.2024.01027","url":null,"abstract":"<p><p>In response to the twin challenges of an aging population and declining birth rates, Zhejiang, China pioneered the concept of \"fertility-friendly hospitals\" in 2022 to support families and individuals in navigating the complexities of childbirth. Although fertility-friendly hospitals have not yet scaled up in number, their potential benefits and the challenges they face are evident. These facilities aim to provide comprehensive services from preconception to postnatal care, necessitating a high level of specialization and resource allocation, with an emphasis on patient education and participatory decision-making. Currently, there is an uneven distribution of resources across regions in China, with the density of maternal and child health care facilities in developed areas exceeding that of less developed regions by more than tenfold. The establishment of fertility-friendly hospitals will help to slow the pace of population aging and mitigate further declines in birth rates, thereby balancing the population composition and promoting long-term equitable social development. However, they also face challenges in balancing resources, improving the quality of services, and improving accessibility across different regions. As the concept is promoted and practiced, fertility-friendly hospitals are expected to become a significant force supporting Chinas population policy.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"218-221"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197165/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rescue of outflow block of the remnant left liver after extended right hemihepatectomy for resection of a tumor in the caudate lobe. 为切除尾状叶肿瘤而进行右半肝切除术后,残余左肝的流出道阻塞得以恢复。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2023.01105
Shohei Kawaguchi, Shiro Onozawa, Hirokazu Momose, Ryota Matsuki, Masaharu Kogure, Yutaka Suzuki, Yoshihiro Sakamoto

Outflow block of the liver is a life-threatening event after living donor liver transplantation. Herein, we rescued a patient suffering from the outflow block of the remnant left hemiliver caused by bending of the left hepatic vein (LHV) after right hemihepatectomy plus caudate lobectomy combined with resection of the middle hepatic vein (MHV). A metastatic tumor sized 6 cm in the caudate lobe of the liver involving the root of the MHV was found in a 50's year old patient after resection of a right breast cancer eight years ago. Right hemihepatectomy and caudate lobectomy combined with resection of the MHV was performed using a two-stage hepatectomy (partial TIPE ALPPS). On day 1, the total bilirubin value increased to 4.5 mg/dL, and a dynamic computed tomography (CT) scan showed the bent LHV. On the diagnosis of outflow block of the left liver, a self-expandable metallic stent was placed in the LHV using an interventional approach, and the pressure in the LHV decreased from 27 cmH2O to 12 cmH2O. The bilirubin value decreased to 1.2 mg/dL on day 3. Outflow block of the LHV can happen after extended right hemihepatectomy with resection of the MHV. Early diagnosis and interventional stenting treatment can rescue the patient from congestive liver failure.

肝脏外流阻断是活体肝移植术后的一个威胁生命的事件。在此,我们抢救了一名在右半肝切除术+尾状叶切除术联合肝中静脉(MHV)切除术后因左肝静脉(LHV)弯曲而导致左半肝残余血流受阻的患者。一位 50 多岁的患者在 8 年前接受右乳腺癌切除术后,发现肝尾叶有一个 6 厘米大小的转移性肿瘤,涉及肝中静脉(MHV)根部。采用两阶段肝切除术(TIPE ALPPS 部分)对患者进行了右半肝切除术和尾状叶切除术,同时切除了 MHV。第 1 天,总胆红素值升至 4.5 mg/dL,动态计算机断层扫描(CT)显示 LHV 弯曲。在诊断出左肝流出道阻塞后,采用介入方法在 LHV 中放置了自膨胀金属支架,LHV 的压力从 27 cmH2O 降至 12 cmH2O。第 3 天,胆红素值降至 1.2 mg/dL。扩大右半肝切除术并切除 MHV 后,可能会出现 LHV 流出阻塞。早期诊断和介入支架治疗可以将患者从充血性肝衰竭中解救出来。
{"title":"Rescue of outflow block of the remnant left liver after extended right hemihepatectomy for resection of a tumor in the caudate lobe.","authors":"Shohei Kawaguchi, Shiro Onozawa, Hirokazu Momose, Ryota Matsuki, Masaharu Kogure, Yutaka Suzuki, Yoshihiro Sakamoto","doi":"10.35772/ghm.2023.01105","DOIUrl":"10.35772/ghm.2023.01105","url":null,"abstract":"<p><p>Outflow block of the liver is a life-threatening event after living donor liver transplantation. Herein, we rescued a patient suffering from the outflow block of the remnant left hemiliver caused by bending of the left hepatic vein (LHV) after right hemihepatectomy plus caudate lobectomy combined with resection of the middle hepatic vein (MHV). A metastatic tumor sized 6 cm in the caudate lobe of the liver involving the root of the MHV was found in a 50's year old patient after resection of a right breast cancer eight years ago. Right hemihepatectomy and caudate lobectomy combined with resection of the MHV was performed using a two-stage hepatectomy (partial TIPE ALPPS). On day 1, the total bilirubin value increased to 4.5 mg/dL, and a dynamic computed tomography (CT) scan showed the bent LHV. On the diagnosis of outflow block of the left liver, a self-expandable metallic stent was placed in the LHV using an interventional approach, and the pressure in the LHV decreased from 27 cmH<sub>2</sub>O to 12 cmH<sub>2</sub>O. The bilirubin value decreased to 1.2 mg/dL on day 3. Outflow block of the LHV can happen after extended right hemihepatectomy with resection of the MHV. Early diagnosis and interventional stenting treatment can rescue the patient from congestive liver failure.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"222-224"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197159/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Updated information concerning trends in suicide rates in elderly in China, 2002-2020. 2002-2020年中国老年人自杀率趋势的最新信息。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2024.01003
Sanmei Wen, Xinyue Wang, Rongfeng Zhou, Tetsuya Asakawa

The aim of this study was to investigate trends in suicide rates (SRs) among the elderly in China. Annual data on SRs among Chinese people ≥ the age of 65 were collected from China's Health Statistics Yearbook from 2002 to 2020. Then, data were stratified by age, region, and sex. Standardized SRs were calculated and analyzed using a conventional joinpoint regression model. Results revealed that overall, SRs among the elderly in China tended to decline from 2002-2020. Fluctuations in SRs, including in 2004-2005 due to the SARS epidemic, in 2009-2010 due to the economic crisis, and in 2019-2020 due to the COVID-19 pandemic, were also observed. Data suggested a relatively greater crude SR among the elderly (vs. young people), in males (vs. females), and in people living in a rural area (vs. those living in an urban area). SRs tended to rise with age. Joinpoint regression analysis identified joinpoints only for males ages 65-69 and over the age of 85 living in a rural area, suggesting that individuals in these groups are more sensitive to negative stimuli and more likely to commit suicide, necessitating closer attention. The findings from this study should help to make policy and devise measures against suicide in the future.

本研究旨在调查中国老年人自杀率(SRs)的变化趋势。研究人员从《中国卫生统计年鉴》中收集了 2002 年至 2020 年中国 65 岁以上老年人自杀率的年度数据。然后,按年龄、地区和性别对数据进行分层。采用传统的连接点回归模型计算和分析标准化SR。结果显示,总体而言,2002-2020年中国老年人的SR呈下降趋势。此外,还观察到 SR 的波动,包括 2004-2005 年因 SARS 疫情、2009-2010 年因经济危机以及 2019-2020 年因 COVID-19 大流行而出现的波动。数据表明,老年人(相对于年轻人)、男性(相对于女性)和农村居民(相对于城市居民)的粗SR相对较高。随着年龄的增长,SR 呈上升趋势。连接点回归分析发现,只有 65-69 岁的男性和居住在农村地区的 85 岁以上的老年人存在连接点,这表明这些人群对负面刺激更敏感,更有可能自杀,因此有必要给予更密切的关注。这项研究的结果应有助于今后制定政策和措施来预防自杀。
{"title":"Updated information concerning trends in suicide rates in elderly in China, 2002-2020.","authors":"Sanmei Wen, Xinyue Wang, Rongfeng Zhou, Tetsuya Asakawa","doi":"10.35772/ghm.2024.01003","DOIUrl":"10.35772/ghm.2024.01003","url":null,"abstract":"<p><p>The aim of this study was to investigate trends in suicide rates (SRs) among the elderly in China. Annual data on SRs among Chinese people ≥ the age of 65 were collected from China's Health Statistics Yearbook from 2002 to 2020. Then, data were stratified by age, region, and sex. Standardized SRs were calculated and analyzed using a conventional joinpoint regression model. Results revealed that overall, SRs among the elderly in China tended to decline from 2002-2020. Fluctuations in SRs, including in 2004-2005 due to the SARS epidemic, in 2009-2010 due to the economic crisis, and in 2019-2020 due to the COVID-19 pandemic, were also observed. Data suggested a relatively greater crude SR among the elderly (<i>vs.</i> young people), in males (<i>vs.</i> females), and in people living in a rural area (<i>vs.</i> those living in an urban area). SRs tended to rise with age. Joinpoint regression analysis identified joinpoints only for males ages 65-69 and over the age of 85 living in a rural area, suggesting that individuals in these groups are more sensitive to negative stimuli and more likely to commit suicide, necessitating closer attention. The findings from this study should help to make policy and devise measures against suicide in the future.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"204-211"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474633","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
BACE1 inhibitor drugs for the treatment of Alzheimer's disease: Lessons learned, challenges to overcome, and future prospects. 治疗阿尔茨海默病的 BACE1 抑制剂药物:汲取的教训、克服的挑战和未来的前景†。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2024.01033
Arun K Ghosh

Alzheimer's disease (AD), first diagnosed over a century ago, remains one of the major healthcare crises around the globe. Currently, there is no cure or effective treatment. The majority of drug development efforts to date have targeted reduction of amyloid-β peptide (Aβ). Drug development through inhibition of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), resulted in promising early clinical studies. However, nearly all small molecule BACE1 inhibitor drugs failed to live up to expectations in later phase clinical trials, due to toxicity and efficacy issues. This commentary aims to provide a brief review of over two decades of BACE1 inhibitor drug development challenges and efforts for treatment of AD and prospects of future BACE1-based drugs.

阿尔茨海默病(AD)在一个多世纪前首次被诊断出来,目前仍是全球主要的医疗危机之一。目前,尚无治愈或有效的治疗方法。迄今为止,大多数药物开发工作都以减少淀粉样蛋白-β肽(Aβ)为目标。通过抑制β位淀粉样前体蛋白裂解酶1(BACE1)进行的药物开发在早期临床研究中取得了良好的效果。然而,由于毒性和疗效问题,几乎所有小分子 BACE1 抑制剂药物在后期临床试验中都未能达到预期效果。本评论旨在简要回顾二十多年来 BACE1 抑制剂药物开发在治疗 AD 方面所面临的挑战和付出的努力,以及未来基于 BACE1 的药物的前景。
{"title":"BACE1 inhibitor drugs for the treatment of Alzheimer's disease: Lessons learned, challenges to overcome, and future prospects<sup>†</sup>.","authors":"Arun K Ghosh","doi":"10.35772/ghm.2024.01033","DOIUrl":"10.35772/ghm.2024.01033","url":null,"abstract":"<p><p>Alzheimer's disease (AD), first diagnosed over a century ago, remains one of the major healthcare crises around the globe. Currently, there is no cure or effective treatment. The majority of drug development efforts to date have targeted reduction of amyloid-β peptide (Aβ). Drug development through inhibition of beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), resulted in promising early clinical studies. However, nearly all small molecule BACE1 inhibitor drugs failed to live up to expectations in later phase clinical trials, due to toxicity and efficacy issues. This commentary aims to provide a brief review of over two decades of BACE1 inhibitor drug development challenges and efforts for treatment of AD and prospects of future BACE1-based drugs.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"164-168"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197157/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467418","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer. 日本转移性阉割敏感性前列腺癌患者前期雄激素受体信号抑制剂与联合雄激素阻断治疗的肿瘤学疗效比较。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2024.01019
Michio Noda, Taketo Kawai, Kanade Hagiwara, Takahiro Yoshida, Kazuki Yanagida, Yuumi Tokura, Itsuki Yoshimura, Tomoyuki Kaneko, Tohru Nakagawa

In recent years, randomized controlled trials have demonstrated that upfront androgen receptor signaling inhibitors (ARSIs) prolong overall survival (OS) compared with androgen deprivation therapy (ADT) alone or combined androgen blockade (CAB) in patients with metastatic castration-sensitive prostate cancer (mCSPC). However, it remains unclear whether upfront ARSI is superior to CAB in Asian populations, among which the efficacy of ADT/CAB is considered relatively high. In this study, we compared the oncological outcomes of upfront ARSI and CAB in Japanese patients with mCSPC. Patients with mCSPC who underwent systemic therapy between May 2009 and October 2023 were enrolled retrospectively. Propensity score matching (PSM) was performed to compare the castration-resistant prostate cancer-free survival (CRPC-FS), cancer-specific survival (CSS), and OS between patients treated with upfront ARSI (ARSI group) and those treated with CAB (CAB group). In total, 30 and 142 patients were enrolled in the ARSI and CAB groups, respectively. After PSM (25 patients in each group), CRPC-FS was significantly longer in the ARSI group than in the CAB group (median: 36.7 vs. 12.3 months, hazard ratio: 0.44, 95% confidence interval: 0.20-0.97, p = 0.035). No significant differences were observed in CSS or OS between the two groups. In conclusion, when compared to CAB, upfront ARSI might have the potential to extend CRPC-FS among individuals in the Japanese population.

近年来,随机对照试验证明,与单纯雄激素剥夺疗法(ADT)或雄激素联合阻断疗法(CAB)相比,前期雄激素受体信号转导抑制剂(ARSI)可延长转移性阉割敏感性前列腺癌(mCSPC)患者的总生存期(OS)。然而,在亚洲人群中,前期 ARSI 是否优于 CAB 仍不清楚,而在亚洲人群中,ADT/CAB 的疗效被认为相对较高。在这项研究中,我们比较了日本 mCSPC 患者前期 ARSI 和 CAB 的肿瘤治疗效果。2009年5月至2023年10月期间接受系统治疗的mCSPC患者均被纳入回顾性研究。采用倾向得分匹配法(PSM)比较了接受前期ARSI治疗的患者(ARSI组)和接受CAB治疗的患者(CAB组)的无阉割耐药前列腺癌生存率(CRPC-FS)、癌症特异性生存率(CSS)和OS。ARSI组和CAB组分别共有30名和142名患者。PSM 后(每组 25 名患者),ARSI 组的 CRPC-FS 明显长于 CAB 组(中位数:36.7 对 12.3):36.7个月对12.3个月,危险比:0.44,95%置信区间:0.20-0.97,P = 0.035)。两组患者的 CSS 和 OS 均无明显差异。总之,在日本人群中,与 CAB 相比,前期 ARSI 有可能延长 CRPC-FS 的时间。
{"title":"Comparison of oncological outcomes of upfront androgen receptor signaling inhibitors and combined androgen blockade in Japanese patients with metastatic castration-sensitive prostate cancer.","authors":"Michio Noda, Taketo Kawai, Kanade Hagiwara, Takahiro Yoshida, Kazuki Yanagida, Yuumi Tokura, Itsuki Yoshimura, Tomoyuki Kaneko, Tohru Nakagawa","doi":"10.35772/ghm.2024.01019","DOIUrl":"10.35772/ghm.2024.01019","url":null,"abstract":"<p><p>In recent years, randomized controlled trials have demonstrated that upfront androgen receptor signaling inhibitors (ARSIs) prolong overall survival (OS) compared with androgen deprivation therapy (ADT) alone or combined androgen blockade (CAB) in patients with metastatic castration-sensitive prostate cancer (mCSPC). However, it remains unclear whether upfront ARSI is superior to CAB in Asian populations, among which the efficacy of ADT/CAB is considered relatively high. In this study, we compared the oncological outcomes of upfront ARSI and CAB in Japanese patients with mCSPC. Patients with mCSPC who underwent systemic therapy between May 2009 and October 2023 were enrolled retrospectively. Propensity score matching (PSM) was performed to compare the castration-resistant prostate cancer-free survival (CRPC-FS), cancer-specific survival (CSS), and OS between patients treated with upfront ARSI (ARSI group) and those treated with CAB (CAB group). In total, 30 and 142 patients were enrolled in the ARSI and CAB groups, respectively. After PSM (25 patients in each group), CRPC-FS was significantly longer in the ARSI group than in the CAB group (median: 36.7 <i>vs.</i> 12.3 months, hazard ratio: 0.44, 95% confidence interval: 0.20-0.97, <i>p</i> = 0.035). No significant differences were observed in CSS or OS between the two groups. In conclusion, when compared to CAB, upfront ARSI might have the potential to extend CRPC-FS among individuals in the Japanese population.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"199-203"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467419","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Low preoperative hemoglobin A1c level is a predictor of perioperative infectious complications after esophagectomy: A retrospective, single-center study. 术前低血红蛋白 A1c 水平是食管切除术后围手术期感染并发症的预测因素:一项回顾性单中心研究。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2023.01113
Daiki Kato, Kazuhiko Yamada, Naoki Enomoto, Syusuke Yagi, Hanako Koda, Kyoko Nohara

This retrospective, single-center study aimed to evaluate the impact of blood glucose (BG) markers on perioperative complications after esophagectomy in a cohort of 176 patients. Study analyses included the correlation of daily maximum BG level and hemoglobin A1c (HbA1c) with clinicopathological factors. Maximum BG levels were significantly higher on postoperative day (POD) 0 than on PODs 2, 3, 5, and 7 (p < 0.05). Additionally, maximum BG levels on PODs 1, 2, and 7 were significantly higher in patients with preoperative HbA1c levels of ≥ 5.6% than in those with preoperative HbA1c levels of < 5.6% (p < 0.05 for all). The rates of any complications and infectious complications were higher in patients with preoperative HbA1c levels of < 5.6% than in those with preoperative HbA1c levels of ≥ 5.6% (p < 0.05 for both). A preoperative HbA1c level of < 5.6% was a significant predictor of infectious complications after esophagectomy by logistic regression analysis (p < 0.05). Maximum BG level after esophagectomy remained high in patients with high preoperative HbA1c levels, whereas a normal HbA1c level was an independent risk factor for infectious complications.

这项回顾性单中心研究旨在评估一组 176 名患者的血糖 (BG) 指标对食管切除术后围手术期并发症的影响。研究分析包括每日最高血糖水平和血红蛋白 A1c (HbA1c) 与临床病理因素的相关性。术后第 0 天(POD)的最高血糖水平明显高于第 2、3、5 和 7 天(P < 0.05)。此外,术前 HbA1c 水平≥ 5.6% 的患者术后第 1、2 和 7 天的最大血糖水平明显高于术前 HbA1c 水平< 5.6% 的患者(P 均<0.05)。术前 HbA1c 水平< 5.6% 的患者发生任何并发症和感染性并发症的比例均高于术前 HbA1c 水平≥ 5.6% 的患者(两者的 P 均<0.05)。通过逻辑回归分析,术前 HbA1c 水平< 5.6% 是食管切除术后感染性并发症的重要预测因素(P < 0.05)。术前 HbA1c 水平高的患者食管切除术后的最大血糖水平仍然很高,而 HbA1c 水平正常则是感染性并发症的独立风险因素。
{"title":"Low preoperative hemoglobin A1c level is a predictor of perioperative infectious complications after esophagectomy: A retrospective, single-center study.","authors":"Daiki Kato, Kazuhiko Yamada, Naoki Enomoto, Syusuke Yagi, Hanako Koda, Kyoko Nohara","doi":"10.35772/ghm.2023.01113","DOIUrl":"10.35772/ghm.2023.01113","url":null,"abstract":"<p><p>This retrospective, single-center study aimed to evaluate the impact of blood glucose (BG) markers on perioperative complications after esophagectomy in a cohort of 176 patients. Study analyses included the correlation of daily maximum BG level and hemoglobin A1c (HbA1c) with clinicopathological factors. Maximum BG levels were significantly higher on postoperative day (POD) 0 than on PODs 2, 3, 5, and 7 (<i>p</i> < 0.05). Additionally, maximum BG levels on PODs 1, 2, and 7 were significantly higher in patients with preoperative HbA1c levels of ≥ 5.6% than in those with preoperative HbA1c levels of < 5.6% (<i>p</i> < 0.05 for all). The rates of any complications and infectious complications were higher in patients with preoperative HbA1c levels of < 5.6% than in those with preoperative HbA1c levels of ≥ 5.6% (<i>p</i> < 0.05 for both). A preoperative HbA1c level of < 5.6% was a significant predictor of infectious complications after esophagectomy by logistic regression analysis (<i>p</i> < 0.05). Maximum BG level after esophagectomy remained high in patients with high preoperative HbA1c levels, whereas a normal HbA1c level was an independent risk factor for infectious complications.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"190-198"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141474632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Gallbladder fossa nodularity in the liver as observed in alcoholic liver disease patients: Analysis based on hepatobiliary phase signal intensity on gadoxetate-enhanced MRI and extracellular volume fraction calculated from routine CT data. 酒精性肝病患者肝脏中的胆囊窝结节:根据钆喷酸增强核磁共振成像的肝胆相信号强度和常规 CT 数据计算的细胞外体积分数进行分析。
IF 1.9 Q3 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH Pub Date : 2024-06-30 DOI: 10.35772/ghm.2023.01085
Keisuke Sato, Shinji Tanaka, Hiroshi Urakawa, Ryo Murayama, Eiko Hisatomi, Yukihisa Takayama, Kengo Yoshimitsu

The purpose of this study is to further verify the concept utilizing signal intensity on hepatobiliary phase (HBP) of gadoxetate-enhanced MRI and extracellular volume fraction (ECV) calculated from CT data. Between Jan 2013 and September 2018, consecutive ALD patients who had both quadruple phase CT and gadoxetate-enhanced MRI within six months were retrospectively recruited. Those who had any intervention or disease involvement around gallbladder fossa were excluded. All images were reviewed and ECV was measured by two experienced radiologists. GBFN grades, and their HBP signal intensity or ECV relative to the surrounding background liver (BGL) were analyzed. There were 48 patients who met the inclusion criteria. There were GBFN grade 0/1/2/3 in 11/15/18/4 patients, respectively. The signal intensity on HBP relative to BGL were iso/slightly high/high in 30/15/3 patients, respectively, and ECV ratio (ECV of GBFN divided by that of BGL) was 0.88 ± 0.18, indicating there are more functioning hepatocytes and less fibrosis in GBFN than in BGL. The GBFN grades were significantly correlated to relative signal intensity at HBP (Spearman's rank correlation, p < 0.01, rho value 0.53), and ECV ratio (p < 0.01, rho value -0.45). Our results suggest GBFN in ALD would represent liver tissues with preserved liver function with less fibrosis, as compared to BGL, which are considered to support our hypothesis as shown above.

本研究旨在进一步验证利用钆塞酸增强 MRI 的肝胆相(HBP)信号强度和 CT 数据计算的细胞外体积分数(ECV)的概念。2013年1月至2018年9月期间,回顾性招募了6个月内同时接受过四重相CT和钆塞酸增强MRI检查的连续ALD患者。排除了胆囊窝周围有任何干预或疾病受累的患者。由两名经验丰富的放射科医生对所有图像进行复查并测量ECV。分析GBFN分级及其相对于周围背景肝脏(BGL)的HBP信号强度或ECV。共有 48 名患者符合纳入标准。11/15/18/4例患者的GBFN等级分别为0/1/2/3。30/15/3例患者的HBP信号强度相对于BGL信号强度分别为等高/略高/高,ECV比值(GBFN的ECV除以BGL的ECV)为0.88 ± 0.18,表明GBFN中的功能肝细胞比BGL中的功能肝细胞多,纤维化程度低。GBFN 分级与 HBP 的相对信号强度(Spearman秩相关,P < 0.01,rho 值 0.53)和 ECV 比值(P < 0.01,rho 值 -0.45)显著相关。我们的研究结果表明,与 BGL 相比,ALD 中的 GBFN 代表肝功能保留且纤维化较少的肝组织,这被认为支持了我们的上述假设。
{"title":"Gallbladder fossa nodularity in the liver as observed in alcoholic liver disease patients: Analysis based on hepatobiliary phase signal intensity on gadoxetate-enhanced MRI and extracellular volume fraction calculated from routine CT data.","authors":"Keisuke Sato, Shinji Tanaka, Hiroshi Urakawa, Ryo Murayama, Eiko Hisatomi, Yukihisa Takayama, Kengo Yoshimitsu","doi":"10.35772/ghm.2023.01085","DOIUrl":"10.35772/ghm.2023.01085","url":null,"abstract":"<p><p>The purpose of this study is to further verify the concept utilizing signal intensity on hepatobiliary phase (HBP) of gadoxetate-enhanced MRI and extracellular volume fraction (ECV) calculated from CT data. Between Jan 2013 and September 2018, consecutive ALD patients who had both quadruple phase CT and gadoxetate-enhanced MRI within six months were retrospectively recruited. Those who had any intervention or disease involvement around gallbladder fossa were excluded. All images were reviewed and ECV was measured by two experienced radiologists. GBFN grades, and their HBP signal intensity or ECV relative to the surrounding background liver (BGL) were analyzed. There were 48 patients who met the inclusion criteria. There were GBFN grade 0/1/2/3 in 11/15/18/4 patients, respectively. The signal intensity on HBP relative to BGL were iso/slightly high/high in 30/15/3 patients, respectively, and ECV ratio (ECV of GBFN divided by that of BGL) was 0.88 ± 0.18, indicating there are more functioning hepatocytes and less fibrosis in GBFN than in BGL. The GBFN grades were significantly correlated to relative signal intensity at HBP (Spearman's rank correlation, <i>p</i> < 0.01, rho value 0.53), and ECV ratio (<i>p</i> < 0.01, rho value -0.45). Our results suggest GBFN in ALD would represent liver tissues with preserved liver function with less fibrosis, as compared to BGL, which are considered to support our hypothesis as shown above.</p>","PeriodicalId":12556,"journal":{"name":"Global health & medicine","volume":"6 3","pages":"183-189"},"PeriodicalIF":1.9,"publicationDate":"2024-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11197160/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141467420","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Global health & medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1